Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
ITRM Stock Chart & Stats
$0.31
-$0.04(-2.14%)
At close: 4:00 PM EST
$0.31
-$0.04(-2.14%)
Day’s Range― - ―
52-Week Range$0.36 - $2.10
Previous CloseN/A
Volume220.96K
Average Volume (3M)813.22K
Market Cap
$16.58M
Enterprise Value$59.27M
Total Cash (Recent Filing)$11.00M
Total Debt (Recent Filing)$33.73M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Mar 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding52,787,678
10 Day Avg. Volume1,119,323
30 Day Avg. Volume813,222
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap3.57
Enterprise Value/Revenue151.97
Enterprise Value/Gross Profit-88.72
Enterprise Value/Ebitda-2.57
Forecast
1Y Price Target
$5.50Price Target Upside1674.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SuperiorityORLYNVAH has demonstrated superiority to conventional antibiotics in late-stage clinical trials, addressing antibiotic resistance.
Market OpportunityORLYNVAH targets uncomplicated urinary tract infections (uUTI) with exclusivity in the US until 2034, creating a significant market opportunity for Iterum.
Product LaunchORLYNVAH became the first and only oral penem antibiotic available in the U.S., providing a new treatment option for patients.
Bears Say
Earnings PerformanceIterum posted an EPS of ($0.20) which was below both internal estimates and consensus.
Market CompetitionThe presence of competing products from companies like GSK in the uUTI market may influence Iterum's stock performance, although ORLYNVAH remains a more attractive therapeutic option.
Sales TrajectoryThe launch trajectory, as expected, given the limited resources and working with Eversana initially focused on 20 territories and working to build the coverage base, is not as steep.
Iterum Therapeutics News
ITRM FAQ
What was Iterum Therapeutics Plc’s price range in the past 12 months?
Iterum Therapeutics Plc lowest stock price was $0.36 and its highest was $2.10 in the past 12 months.
What is Iterum Therapeutics Plc’s market cap?
Iterum Therapeutics Plc’s market cap is $16.58M.
When is Iterum Therapeutics Plc’s upcoming earnings report date?
Iterum Therapeutics Plc’s upcoming earnings report date is Mar 12, 2026 which is in 75 days.
How were Iterum Therapeutics Plc’s earnings last quarter?
Iterum Therapeutics Plc released its earnings results on Nov 14, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.07.
Is Iterum Therapeutics Plc overvalued?
According to Wall Street analysts Iterum Therapeutics Plc’s price is currently Undervalued.
Does Iterum Therapeutics Plc pay dividends?
Iterum Therapeutics Plc does not currently pay dividends.
What is Iterum Therapeutics Plc’s EPS estimate?
Iterum Therapeutics Plc’s EPS estimate is -0.15.
How many shares outstanding does Iterum Therapeutics Plc have?
Iterum Therapeutics Plc has 52,787,678 shares outstanding.
What happened to Iterum Therapeutics Plc’s price movement after its last earnings report?
Iterum Therapeutics Plc reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -16.071%.
Which hedge fund is a major shareholder of Iterum Therapeutics Plc?
Currently, no hedge funds are holding shares in ITRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iterum Therapeutics Plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
ITRM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.View all ITRM earnings summariesITRM Stock 12 Month Forecast
Average Price Target
$5.50
▲(1674.19% Upside)
Technical Analysis
Cel-Sci
―
Clene
―
Xilio Therapeutics
―
CAMP4 Therapeutics Corporation
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
1.11% Insiders
0.02% Mutual Funds
1.02% Other Institutional Investors
97.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---